Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Pinealon -- also known by its amino acid sequence designation EDR (Glu-Asp-Arg) -- is a synthetic tripeptide (3 amino acids) developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. The compound was identified through systematic fractionation of Cortexin -- the polypeptide neuroprotective preparation derived from bovine cerebral cortex tissue that has been used clinically in Russia and Eastern Europe for decades -- to identify the minimum active sequence retaining neuroprotective effects.
Important nomenclature clarification: Despite the name "Pinealon" suggesting pineal origin, the compound was actually isolated from cerebral cortex extract (Cortexin), not pineal tissue. The name refers to its proposed effects on the pineal-CNS axis and brain biology, not its anatomical origin. This is a common source of confusion in the literature.
Pinealon represents the third Khavinson compound in this library, joining:
- Epitalon (AEDG tetrapeptide; pineal-derived; telomerase activation, geroprotection)
- Thymalin (Glu-Trp dipeptide; thymus-derived; immune restoration)
- Pinealon (EDR tripeptide; cortex-derived but brain-targeting; neuroprotection)
This trio establishes the Khavinson peptide bioregulator framework in the library, covering the three major tissue-specific targets (pineal, thymus, brain).
Pinealon's primary research focus is neuroprotection and cognitive aging -- distinct from Epitalon's telomere/anti-aging focus and Thymalin's immune focus. The compound has demonstrated:
- Neuroprotective effects in oxidative stress, hypoxia, and ischemia models
- Reduced neuronal apoptosis
- Preserved mitochondrial membrane potential
- Cognitive improvement in aged animals
- Antioxidant enzyme upregulation
- Anti-inflammatory effects
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Subcutaneous Pinealon | Short (~30-60 minutes) |
| Oral Pinealon | Variable; affected by GI degradation |
| Intramuscular Pinealon | Short |
| Sublingual Pinealon | Variable |
What it does
Main effects
- Neuroprotection in oxidative stress, hypoxia, and ischemia models -- reduced neuronal apoptosis, preserved mitochondrial membrane potential
- Antioxidant enzyme upregulation -- SOD2 (superoxide dismutase 2) upregulation; ROS reduction in neuronal cultures; lipid peroxidation attenuation in aged brain tissue
- Cognitive improvement in aged animals -- improved learning task performance, memory preservation in age-related cognitive decline models
- Anti-apoptotic effects -- reduced caspase activation, Bcl-2 family modulation, neuronal survival enhancement
- MAPK-ERK1/2 pathway modulation -- EDR delays homocysteine-induced ERK1/2 activation; protection against homocysteine toxicity PMC: 7795577
- Anti-inflammatory effects -- reduced inflammatory cytokine production, NF-kB pathway effects, modulation of neutrophil activation
- Mitochondrial membrane potential preservation -- mitochondrial morphology effects, bioenergetic preservation
- Melatonin pathway modulation (pineal-related) -- proposed influence on melatonin synthesis, circadian rhythm effects, sleep quality effects despite cortical origin
- Blood-brain barrier penetration -- demonstrated; CNS as primary therapeutic target; direct cellular and nuclear entry
- Notable oral bioavailability for a peptide -- practical advantage of the small tripeptide size; simpler administration vs injection
What to watch for
Common side effects
- Generally well-tolerated across Russian research; no major adverse events documented; acceptable safety in cell culture and animal studies
- Injection site reactions -- mild, uncommon for subcutaneous administration
- Limited long-term human controlled data -- Khavinson-framework research covers short, intermittent exposure periods; effects of continuous long-term use are unclear
- Theoretical cancer biology concern -- effects on cell proliferation/survival; theoretical implications for cancer biology; limited Western data; avoid in active malignancy
- Research chemical quality concerns -- concentration accuracy variable, sterility for injection required; identity and content of unregulated material are unverified
- Not WADA-prohibited as of current information (verify before use in tested sport)
- Most research from Khavinson laboratory -- limited independent Western replication; methodological standards differ from Western pharmaceutical
Key facts
Key facts worth knowing
- Pinealon is a synthetic tripeptide with sequence Glu-Asp-Arg (E-D-R, L-glutamic acid - L-aspartic acid - L-arginine). Molecular weight 418.40 Da. The "EDR" designation is increasingly used in scientific literature alongside "Pinealon."
- Isolated from Cortexin (not pineal gland despite the name). Cortexin is a polypeptide neuroprotective drug derived from bovine cerebral cortex tissue, used clinically in Russia and Eastern Europe for decades for stroke, traumatic brain injury, and epilepsy.
- Developed by Khavinson's team at the St. Petersburg Institute of Bioregulation and Gerontology. Identified as one of the shortest and most active peptide sequences within Cortexin responsible for neuroprotective effects. Pinealon is the Cytogen counterpart to Cortexin (the Cytomax).
- Three amino acid structure is significant: smallest neuroprotective peptide in the Khavinson family; notable oral bioavailability (unusual for peptides); blood-brain barrier penetration demonstrated; direct cellular entry facilitated by small size.
- Proposed primary mechanism (Khavinson framework): direct DNA interaction with regulatory sequences in CNS-specific genes; epigenetic modulation of gene expression; restoration of "youthful" expression patterns in aged neurons; modulation of antioxidant enzyme transcription; anti-apoptotic gene expression support.
- EDR and Alzheimer's research: Recent papers have specifically investigated EDR/Pinealon in Alzheimer's disease context, particularly its effects on protein synthesis and gene expression relevant to AD pathology. PMC: 7795577 demonstrates EDR delays homocysteine-induced ERK1/2 activation from 2.5 minutes to 20 minutes in neuronal cultures. PMC: 7795577
- Studied alongside other Khavinson peptides: Pinealon (cortex-derived, brain-targeting) and Epitalon (pineal-derived, systemic) are described in the Khavinson literature as acting on different tissue targets. No controlled data establishes whether combined exposure differs from either compound alone.
- WADA status: Not specifically prohibited as of current information. Legal status: No FDA approval. Substantial Russian preclinical research. Not on FDA bulk drug substance lists.
Legal status
Legal status
No FDA approval. Substantial Russian preclinical research. Not on FDA bulk drug substance lists. Not WADA-prohibited (verify current status before use in tested sport). Cortexin (the parent polypeptide) is approved in Russia and Eastern Europe; Pinealon/EDR the synthetic tripeptide is research-only worldwide.